Redeye returns with an update following Genovis’ licensing deal with Selecta Biosciences – a deal that clearly validates the huge potential in the company and its SmartEnzymes. We have hiked our fair value range and argue that the stock is very attractive for the long-term investor thanks to significant optionality on the upside.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/